For the treatment of dry eye syndrome as a complication migrated ophthalmopathy

 

(57) Abstract:

The invention relates to ophthalmology and is intended for the treatment of dry eye syndrome (DES) after suffering ophthalmopathy, as well as for treatment of SHBG other etiology. For treatment includes poliglyukin and autovolume patient ratio of 1:1 and the antioxidant carnosine content of not more than 0.2%. The tool provides for the formation of stable precorneal tear film and the achievement of the compensation of the pathological process.

The invention relates to ophthalmology, and can be used for the treatment of dry eye syndrome (DES) in patients undergoing viral diseases of the anterior segment of the eye. The treatment algorithm of ophthalmopathy well prepared and relief of acute process is achieved in minimum time. However, some time later, patients receive complaints about discomfort, redness, burning, itching, etc. When you return to the ophthalmologist this condition is often estimated as a recurrent viral disease and is prescribed appropriate therapy. The use of potent drugs leads to deterioration and weighting process. The reason for repeating the th acute viral process.

There are various ways to treat dry eye syndrome based on the use of drugs, artificial tears, often in combination with other drugs. The aim of tear replacement therapy is the creation of stable precorneal tear film, providing mechanical, immune defense and tissue nutrition anterior segment of the eye. The disadvantages of these methods of treatment is individual intolerance to the drugs, artificial tears, the occurrence of toxic and allergic reactions, addiction and low efficiency. In addition, tear replacement drugs are generic tools that are not tied to the specific patient.

Analog of the present invention is a drug poliglyukin. Poliglyukin is a solution of medium molecular fractions of partially hydrolyzed dextran in isotonic sodium chloride. As plazmozameschayuschim drug, poliglyukin as close as possible to the molecular mass of albumin in the blood, long-term circulating in the blood line. Relative viscosity and pH poliglyukin similar to the tear, allowing you to use it as a product of artificial tears. (Pozo is Y.” M, 2002) the Drug is prescribed in installations 6-12 times a day. The disadvantage of this drug is the idiosyncrasy, the occurrence of toxic and allergic reactions, formation of insufficiently stable tear film, is not always ensured long-term therapeutic effect.

The closest analogue is poliglyukin in combination with taufona. Taufon improves energy processes, stimulates reparative processes, is used as an antioxidant. The drug is administered 4 to 6 times a day. The shortcomings of the tools are the same as those poliglyukina possible idiosyncrasy taufona. (Manual for doctors “Methods of diagnosis of dry eye syndrome patients after adenoviral ophthalmopathy.” M., 2002.)

The task of the invention is to create medicines for the treatment of dry eye syndrome after suffering ophthalmopathy. A course of treatment using this tool allows you to ensure the formation of stable precorneal tear film that prevents further development disorders and helps to restore lesoproduktsii.

The technical result from the proposed Lekarstvo the following migrated ophthalmopathy. The technical result is achieved through the use of autoseparate patient as a drug that imitates in its biochemical composition of the tears of the individual patient. The presence of carnosine in a certain concentration can accelerate the metabolic processes in the tissues of the conjunctiva. Carnosine is also used as antioxidant.

For implementing the method using the claimed means produce the sampling of venous blood from the patient, centrifuged at a speed of 1000 revolutions per minute Exfoliating serum pumped into a sterile vial, add poliglyukin in the ratio of 1:1 and carnosine as an antioxidant and stabilizer in percentage concentration of not more than 0.2%.

Poliglyukin provides sufficient viscosity of the drug, its pH. Autoseparate optimally approximates the biochemical composition of funds to the composition of their own tears of the patient.

Carnosine is used as an antioxidant, stabilizer means, and also accelerates the energy processes in the tissues of the conjunctiva and cornea.

The value of drugs is an optimal combination for the formation of stabile effect and the possibility of prevention of SHBG after suffering ophthalmopathy.

The drug is used in installations 6-12 times a day. If necessary to the treatment of add reparative and anti-allergic drugs.

The proposed tool has received 36 patients ranging in age from 24 to 68 years, 26 women, 10 men. The observation period from 1 to 12 months.

Example 1.

Patient N., 1952.

In 1998 he moved adenoviral conjunctivitis. In the acute period received standard therapy: interferon, starcaller, sulfacetamide, antihistamines inside. During treatment showed positive and in 2 weeks the patient was healthy. A month later, the patient had a feeling of contamination of the eyes, occasional redness, burning, fatigue. With repeated handling diagnosed violation of lesoproduktsii and development of dry eye. In the course of treatment was used the whole range of drugs, artificial tears, both domestic and imported. It was noted weak positive trend with subsequent allergic reaction of the conjunctiva and the need to replace the drug. In this case, autoseparate with carnosine allowed to attain a stable (within a few the Arata - the absence of allergic reactions during treatment and improvement of subjective sensations. Managed to stabilize the process and to prevent the inclusion in the pathological process of the cornea.

Example 2.

Patient H., born in 1932.

First contacted IRI GB of them. Helmholtz in 2000 with a diagnosis of OS - herpetic keratitis. A course of standard therapy ointment zovirax, vitasek, sulfacetamide, desensibilizing drugs inside has helped to offset the acute process and the formation of lung opacities of the cornea. However, the corneal epithelium was periodically clusively forming zone staining fluorescein, and there was a point epitheliopathy, accompanied by the relevant complaints. After the diagnostic study was diagnosed with OS - keratoconjunctivitis sicca. Attempts selection of tear replacement therapy produced no positive clinical dynamics - continued point epitheliopathy. It should also be noted poor tolerability of the drugs the patient is a burning sensation, a tightening of the eyes, redness, itching within 15-30 min after instillation.

Try the instillation of autoseparate with carnosine this patient helped improve the registered discomfort after instillation. Thus, the proposed remedy, including poliglyukin and antioxidant (carnosine), characterized in that it additionally contains autovolume patient, allows to achieve a stable precorneal tear film, providing full mechanical protection, has a reparative effect and has good portability. The tool can be used to prevent the development of dry eye syndrome after suffering ophthalmopathy, and to treat other types of SHBG - S. of Segren, systemic pathology, and other diseases causing lesions of the cornea, including after previous refractive surgeries, in particular Lasic.

For the treatment of dry eye syndrome as a complication migrated ophthalmopathy, including poliglyukin and antioxidant, characterized in that it further comprises autovolume ratio poliglyukina and autoseparate is 1:1, and the content of the antioxidant carnosine not more than 0.2%.



 

Same patents:
The invention relates to medicine, namely to ophthalmology, and can be used in the operations
The invention relates to medicine, ophthalmology

The invention relates to medicine, namely to the pharmacy and is used for treatment of keratitis and conjunctivitis

The invention relates to ophthalmology and is intended for operations as retinal detachment and progressive myopia
The invention relates to the field of medicine
Eye film // 2232582
The invention relates to medicine, in particular to ophthalmology
The invention relates to agriculture, in particular animal health, and can be used to treat horses, patients relapsing iridocyclitis
The invention relates to agriculture, in particular animal health, and can be used to treat horses, patients relapsing iridocyclitis
The invention relates to medicine, Hematology, cardiology and endocrinology and can be used for normalization of platelet aggregation in patients with metabolic syndrome

The invention relates to veterinary

The invention relates to veterinary science and medicine, in particular to the prevention of brucellosis infection

The invention relates to the field of biotechnology, specifically to means of stimulating preparirovanie damage cells, and may be used in therapy and cosmetology

The invention relates to medicine, namely to the gastroenterologist, and for the treatment of patients with gastroduodenal diseases system

The invention relates to a derivative of erythromycin formulas (I)

in which Y denotes a hydrogen atom or fluorine; n denotes an integer from 1 to 8; Z represents a hydrogen atom or a residue of carboxylic acid, and in which pyrazol cycle substituted heteroaryl radical, which contains one nitrogen atom; and their salt adducts with tilotama

The invention relates to the field of medicine and veterinary medicine and relates to new compounds with anti-TB activity and represents a p-guanidinosuccinic sodium formula 1

The invention relates to the field of medicine and veterinary medicine and relates to new compounds with anti-TB activity and represents a p-guanidinosuccinic sodium formula 1

The invention relates to the field of medicine and for the treatment of colds and flu, namely the combined drug for the relief of symptoms of colds and flu, containing acetylsalicylic acid component selected from the group: Metamizole, paracetamol, ibuprofen, antihistamine agent, selected from the group of promethazine, Pheniramine, terfenadine, astemizole, acrivastine, loratadine, Fexofenadine, and phenylephrine and ascorbic acid, as well as a combined preparation for the relief of symptoms of colds and flu, containing Metamizole, paracetamol or ibuprofen, antihistamine agent, selected from the group of promethazine, Pheniramine, terfenadine, astemizole, acrivastine, loratadine, Fexofenadine, and phenylephrine and ascorbic acid

The invention relates to the pharmaceutical industry and relates to a drug for treatment and prevention of pathological lesions of blood vessels and tissues
Up!